Astellas Pharma Gmbh

Takaho Nomura

Ryushi Seo

Hidenori Azami

Satoshi Yamamoto

Hirofumi Yamamoto

Hiroyuki Kaizawa

Hideki Kubota

Kazuyuki Tsuchiya

Kazunori Kamijo

Mari Sugita

Akira Suga

Toru Watanabe

Keizo Sugasawa

Kenichi Kawaguchi

Shunichiro Matsumoto

Tomoaki Abe

Takashi Shin

Masayuki Tanahashi

Substituted imidazo[1,5-a]quinoxalin-4-ones are useful as phosphodiesterase 9 inhibitors.

Substituted imidazo[1,5-a]quinoxalin-4-ones as phosphodiesterase 9 inhibitors

Substituted imidazo[1,5-a]quinoxalin-4(5H)-ones are useful as PDE9 inhibitors.

Substituted imidazo[1,5-a]quinoxalin-4(5H)-ones as PDE9 inhibitors

[Object] To provide a therapeutic and/or prophylactic agent for urinary frequency, urinary urgency, and urinary incontinence associated with various lower urinary tract diseases including overactive bladder, various lower urinary tract diseases accompanied by lower urinary tract pain, such as interstitial cystitis, chronic prostatitis, and the like, and various diseases accompanied by pain, based on an excellent trkA receptor inhibitory action. [Means for Solution] A novel azolecarboxamide compound in which a thiazole ring or an oxazole ring is bonded to a benzene ring, a pyridine ring, a pyridazine ring, a thiophene ring, a pyrazole ring or a pyrrole ring through carboxamide, or a salt thereof is confirmed to have a potent trkA receptor inhibitory activity, and found to be capable of being used as a therapeutic and/or prophylactic agent which is excellent in efficacy and safety for urinary frequency, urinary urgency, and urinary incontinence associated with various lower urinary tract diseases including overactive bladder, various lower urinary tract diseases accompanied by lower urinary tract pain, such as interstitial cystitis, chronic prostatitis, and the like, and various diseases accompanied by pain, thereby completing the present invention.

Azolecarboxamide compound or salt thereof

Growing community of inventors

Tokyo, Japan

Takaho Nomura